Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb;101(2):317-332.
doi: 10.1007/s00277-021-04689-4. Epub 2021 Oct 6.

Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

Affiliations
Clinical Trial

Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

Alexandra-Cristina Paunescu et al. Ann Hematol. 2022 Feb.

Erratum in

Abstract

Health-related quality of life (HRQoL) is a multidimensional concept including physical, emotional, social, and cognitive functions, disease symptoms, and side effects of treatment. Differences in HRQoL due to gender, existence of comorbidities, and number of chemotherapy cycles are little explored in diffuse large B-cell lymphoma (DLBCL) survivors. Our objective was to investigate whether differences in HRQoL in function of these factors exist 1 year after the diagnosis of DLBCL. One hundred and one patients, enrolled in the RT3 (Real-Time Tailored Therapy) Study, answered self-administrated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), EORTC High-Grade Non-Hodgkin Lymphoma (NHL-HG29), Hospital Anxiety and Depression Scale (HADS), Post Traumatic Growth Inventory (PTGI), and Multidimensional Fatigue Inventory (MFI) questionnaires. Adjusted means of scores were calculated in multivariate linear regression models. Fifty-seven survivors (mean age of 58.5 years) answered all questionnaires. Women have significantly higher scores of posttraumatic growth and lower physical functioning than men (P < 0.04). Survivors with comorbidities have increased physical fatigue and symptom burden, increased emotional impact, mental fatigue and depression, and reduced physical functioning and global health status (all P < 0.05). A greater number of cycles of chemotherapy increase the level of symptoms (pain, neuropathy, and dyspnoea; P < 0.05). The various aspects related to HRQoL should be discussed with DLBCL patients and investigated, with the aim of developing strategies to ensure appropriate psychosocial and supportive care and to improve the HRQoL in these patients.

Keywords: Chemotherapy; Comorbidities; Lymphoma; Quality of life; Survivors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1.
Fig. 1.
Study diagram
Fig. 2.
Fig. 2.
Comparisons of EORTC QLQ-C30 scores of DLBCL patients participating in the Lymphoma Quality of Life Study and general French population reference values. EORTC QLQ-C30 mean scores in DLBCL patients and reference values in France [Nolte et al., 2019]. Abbreviations: QL, global health status; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive function; SF, social functioning; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnoea; SL, insomnia; AP, appetite loss; CO, constipation; DI, diarrhoea; FI, financial difficulties. ** P < 0.01; * P < 0.05

References

    1. Sapkota S, Shaikh H (2021) Non-Hodgkin lymphoma. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing - PubMed
    1. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23(26):6351–6357. doi: 10.1200/JCO.2005.05.012. - DOI - PubMed
    1. Defossez G, Le Guyader-Peyrou S, Uhry Z, Grosclaude P, Colonna M, Dantony E, et al. Overview. Saint-Maurice: Santé publique France; 2019. National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018.
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed
    1. Chaganti S, Illidge T, Barrington S, Mckay P, Linton K, Cwynarski K, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43–56. doi: 10.1111/bjh.14136. - DOI - PubMed

Publication types